Strategic Expansion with Leading Franchise Network Underscores Revenue Potential and Market Leadership for SteraMist iHP TechnologyFREDERICK, Md., Oct. 01, 2025…
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of…
Cambridge, UK, 1 October 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G…
Primary’s cloud-based system modernizes state newborn screening tracking and follow-up, incorporating cutting-edge science, evidence-based clinical protocols, and emerging screening methodologies…
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting…
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica…
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical…
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc.…
Plans to reach nearly 8.3 million Medicare-eligible adults across five states during annual enrollment period, Oct. 15-Dec. 7ORANGE, Calif., Oct.…
PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with…